Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic HCV infection prior to study enrollment.~2. Screening laboratory results from the central clinical laboratory indicating HCV genotype 2 or 3 infection only (no mixed genotype).~3. Absence OR presence of cirrhosis.~4. If cirrhotic, need to have compensated cirrhosis and absence of hepatocellular carcinoma (HCC)~Exclusion Criteria:~1. Positive screen for hepatitis B surface antigen or anti-human immunodeficiency virus antibody~2. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse.~3. Current enrollment in another clinical study, previous enrolment in this study, or previous use of any investigational or commercially available anti-HCV therapy (other than interferon, pegIFN, RBV, and or SOF) including previous exposure to telaprevir, boceprevir, ABT-450, or ombitasvir (ABT-267).~4. Subjects without cirrhosis: Any current or past clinical evidence of cirrhosis.~5. Abnormal lab tests.~6. Females who are pregnant or plan to become pregnant or breastfeeding, or males whose partners are pregnant or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (genotype [GT]3, noncirrhotic) (Type: EXPERIMENTAL): Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
- Arm B (GT3, noncirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily \[BID\]) for 12 weeks.
- Arm C (GT2, noncirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
- Arm D (GT2, noncirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
- Arm E (GT3, cirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
- Arm F (GT3, noncirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).